<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abionyx Pharma Sa — News on 6ix</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1</link>
<description>Latest news and press releases for Abionyx Pharma Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abionyx-pharma-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52744beedb30cb6f69b5d.webp</url>
<title>Abionyx Pharma Sa</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1</link>
</image>
<item>
<title>ABIONYX Pharma Achieves Major Milestone in apoA-I Biomanufacturing with Breakthrough in Synthetic Sphingomyelin Production</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-achieves-major-milestone-in-apoa-i-biomanufacturing-with-breakthrough-in-synthetic-sphingomyelin-production-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-achieves-major-milestone-in-apoa-i-biomanufacturing-with-breakthrough-in-synthetic-sphingomyelin-production-1</guid>
<pubDate>Fri, 27 Mar 2026 06:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., March 27, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an exclusive apoA-I technology platform, today announced a significant technological and industrial breakthrough combining high-performance apoA-I bioproduction with exclusive mastery of ultra-pure synthetic sphingomyelin, paving the way for a new class</description>
</item>
<item>
<title>ABIONYX Pharma: Availability of the Universal Registration Document for the year 2025</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-availability-of-the-universal-registration-document-for-the-year-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-availability-of-the-universal-registration-document-for-the-year-2025-1</guid>
<pubDate>Tue, 17 Mar 2026 18:26:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., March 17, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an exclusive apoA-I technology platform, today announces that it has filed its Universal Registration Document with the Autorité des Marchés Financiers (AMF) on March 17, 2026 (filing number : D. 26-0099) for the fiscal year ended December 31, 2025.</description>
</item>
<item>
<title>ABIONYX Pharma Announces Its 2025 Annual Results</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-its-2025-annual-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-its-2025-annual-results-1</guid>
<pubDate>Thu, 12 Mar 2026 17:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., March 12, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an exclusive apoA-I technology platform, today discloses its 2025 annual results as approved by all members of the Board of Directors and provides an update on its activity to date. The audit procedures on the consolidated financial statements have been</description>
</item>
<item>
<title>ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-provides-an-update-on-its-business-and-cash-position-for-the-4th-quarter-of-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-provides-an-update-on-its-business-and-cash-position-for-the-4th-quarter-of-2025-1</guid>
<pubDate>Thu, 26 Feb 2026 17:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., February 26, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today provided an update on business and cash flow for the fourth quarter ended December 31, 2025.</description>
</item>
<item>
<title>ABIONYX Pharma Announces Its Financial Calendar for the Year 2026</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-its-financial-calendar-for-the-year-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-its-financial-calendar-for-the-year-2026-1</guid>
<pubDate>Fri, 23 Jan 2026 18:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., January 23, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.</description>
</item>
<item>
<title>ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-carries-out-a-capital-increase-with-cancellation-of-preferential-subscription-rights-in-favor-of-certain-categories-of-persons-amounting-to-approximately-euro18m-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-carries-out-a-capital-increase-with-cancellation-of-preferential-subscription-rights-in-favor-of-certain-categories-of-persons-amounting-to-approximately-euro18m-1</guid>
<pubDate>Wed, 17 Dec 2025 06:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., December 17, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today carries out a capital increase with the removal of preferential subscription rights ("PSR") for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new sh</description>
</item>
<item>
<title>ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-is-launching-a-capital-increase-with-cancellation-of-preferential-subscription-rights-in-favor-of-certain-categories-of-persons-amounting-to-approximately-euro18m-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-is-launching-a-capital-increase-with-cancellation-of-preferential-subscription-rights-in-favor-of-certain-categories-of-persons-amounting-to-approximately-euro18m-1</guid>
<pubDate>Tue, 16 Dec 2025 20:17:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., December 16, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights ("PSR") for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 58</description>
</item>
<item>
<title>ABIONYX Pharma Reports on Its Business and Cash Position for the Third Quarter of 2025</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-reports-on-its-business-and-cash-position-for-the-third-quarter-of-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-reports-on-its-business-and-cash-position-for-the-third-quarter-of-2025-1</guid>
<pubDate>Tue, 25 Nov 2025 17:33:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., November 25, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), ), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today provided an update on business and cash flow for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-and-sebia-announce-an-exclusive-global-strategic-partnership-to-transform-sepsis-diagnosis-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-and-sebia-announce-an-exclusive-global-strategic-partnership-to-transform-sepsis-diagnosis-1</guid>
<pubDate>Thu, 20 Nov 2025 17:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif. & LISSES, France, November 20, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, and SEBIA, a global player in specialized biological diagnostics, today announced an exclusive global strategic partnership in sepsis.</description>
</item>
<item>
<title>ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-enters-advanced-strategic-discussions-with-ihu-sepsis-the-worlds-first-center-dedicated-to-sepsis-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-enters-advanced-strategic-discussions-with-ihu-sepsis-the-worlds-first-center-dedicated-to-sepsis-1</guid>
<pubDate>Wed, 12 Nov 2025 06:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., November 12, 2025--ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced strategic discussions with IHU SEPSIS, the world’s first and largest integrated center fully dedicated to the research, training, and clinical management of sepsis.</description>
</item>
<item>
<title>ABIONYX Pharma Announces Advanced Strategic Discussions with IHU SEPSIS, the World's Leading Center Dedicated to Sepsis</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-advanced-strategic-discussions-with-ihu-sepsis-the-worlds-leading-center-dedicated-to-sepsis-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-advanced-strategic-discussions-with-ihu-sepsis-the-worlds-leading-center-dedicated-to-sepsis-1</guid>
<pubDate>Wed, 12 Nov 2025 06:00:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., November 12, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announced that it has entered into advanced strategic discussions with IHU SEPSIS, the world’s first integrated research, training, and clinical care center fully dedicated to sepsis.</description>
</item>
<item>
<title>ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis-1</guid>
<pubDate>Tue, 21 Oct 2025 16:49:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., October 21, 2025--ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio titled "Plasma apolipoprotein A-I is a causal protective factor in sepsis." (https://www.nature.com/articles/s41598-025-19204-2#auth-Keith_R_-Walley-Aff1)</description>
</item>
<item>
<title>ABIONYX Pharma: 2025 Half-Year Financial Results</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-2025-half-year-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-2025-half-year-financial-results-1</guid>
<pubDate>Thu, 25 Sep 2025 18:16:00 GMT</pubDate>
<description>TOULOUSE, France & FULLERTON, Calif., September 25, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant apoA-1, today announces its financial results for the first half of 2025.</description>
</item>
<item>
<title>ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-provides-an-update-on-its-activity-and-cash-position-for-the-2nd-quarter-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-provides-an-update-on-its-activity-and-cash-position-for-the-2nd-quarter-2025-1</guid>
<pubDate>Thu, 28 Aug 2025 16:51:00 GMT</pubDate>
<description>TOULOUSE, France & LAKELAND, Mich., August 28, 2025--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today provides an update on its activity and cash position as of June 30, 2025.</description>
</item>
<item>
<title>ABIONYX Pharma Announces the Start of Discussions With a Major Player in the Field of Sepsis for a Strategic Partnership</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-the-start-of-discussions-with-a-major-player-in-the-field-of-sepsis-for-a-strategic-partnership-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-the-start-of-discussions-with-a-major-player-in-the-field-of-sepsis-for-a-strategic-partnership-1</guid>
<pubDate>Wed, 27 Aug 2025 17:26:00 GMT</pubDate>
<description>TOULOUSE, France & LAKELAND, Mich., August 27, 2025--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announced today that it has entered into discussions with a leading partner in sepsis.</description>
</item>
<item>
<title>ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-approval-of-all-resolutions-put-to-the-vote-at-its-combined-general-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-announces-approval-of-all-resolutions-put-to-the-vote-at-its-combined-general-meeting-1</guid>
<pubDate>Fri, 27 Jun 2025 17:14:00 GMT</pubDate>
<description>TOULOUSE, France & LAKELAND, Mich., June 27, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were approved.</description>
</item>
<item>
<title>ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2025</title>
<link>https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-provides-an-update-on-its-activity-and-cash-position-for-the-1st-quarter-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/abionyx-pharma-sa-1/news/abionyx-pharma-provides-an-update-on-its-activity-and-cash-position-for-the-1st-quarter-2025-1</guid>
<pubDate>Wed, 28 May 2025 16:00:00 GMT</pubDate>
<description>TOULOUSE, France & LAKELAND, Mich., May 28, 2025--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2025.</description>
</item>
</channel>
</rss>